&lt;p&gt;Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome&lt;/p&gt;

Ding, Qunli; Sun, Shifang; Zhang, Yun; Tang, Pan; Lv, Chengna; Ma, Hongying; Yu, Yiming; Xu, Suling; Deng, Zaichun

doi:10.2147/copd.s233461

Cited by 24 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Biomarkers Of Acomentioning

confidence: 99%

“…The serum levels of IL-9, vascular endothelial growth factor A (VEGFA) and placental growth factor (PIGF) in patients with ACO are significantly higher than in non-ACO asthmatics, while the levels of IL-8 and IL-17A are lower in ACO compared to asthmatics. 63 Recently, it was reported that 11 metabolites: serine, threonine, ethanolamine, glucose, cholesterol, 2-palmitoylglycerol, stearic acid, lactic acid, linoleic acid, D-mannose, and succinic acid, were found to be significantly altered in ACO as compared with asthma or COPD. 64 This provides novel insights into metabolic pathways and inflammatory mediators involved in the mechanisms underlying ACO and how these processes may be linked to each other and also with the pulmonary function impairment.…”

Section: Biomarkers Of Acomentioning

confidence: 99%

See 1 more Smart Citation

Update on Asthma–COPD Overlap (ACO): A Narrative Review

Mekov¹,

Núñez²,

Sin³

et al. 2021

COPD

View full text Add to dashboard Cite

Although chronic obstructive pulmonary disease (COPD) and asthma are well-characterized diseases, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was introduced to describe patients that have clinical features of both diseases and may represent around 25% of COPD patients and around 20% of asthma patients. Despite the increasing interest in ACO, there are still substantial controversies regarding its definition and its position within clinical guidelines for patients with obstructive lung disease. In general, most definitions indicate that ACO patients must present with non-reversible airflow limitation, significant exposure to smoking or other noxious particles or gases, together with features of asthma. In patients with a primary diagnosis of COPD, the identification of ACO has therapeutic implication because the asthmatic component should be treated with inhaled corticosteroids and some studies suggest that the most severe patients may respond to biological agents indicated for severe asthma. This manuscript aims to summarize the current state-of-the-art of ACO. The definitions, prevalence, and clinical manifestations will be reviewed and some innovative aspects, such as genetics, epigenetics, and biomarkers will be addressed. Lastly, the management and prognosis will be outlined as well as the position of ACO in the COPD and asthma guidelines.

show abstract

Section: Biomarkers Of Acomentioning

confidence: 99%

Section: Biomarkers Of Acomentioning

confidence: 99%

Update on Asthma–COPD Overlap (ACO): A Narrative Review

Mekov¹,

Núñez²,

Sin³

et al. 2021

COPD

View full text Add to dashboard Cite

show abstract

“…For example, Ding et al demonstrated that the serum VEGFA is one promising diagnostic biomarker of asthma-COPD overlap syndrome. 21 In addition, evidence suggested that SIRT1 and FOXO1 mRNA expression levels in PBMCs correlate to physical activity in COPD patients. 22 We intend to explore more potential autophagyrelated genes of COPD in the future.…”

mentioning

confidence: 99%

Identification and Validation of Autophagy-Related Genes in Chronic Obstructive Pulmonary Disease

Sun¹,

Shen²,

Wang³

et al. 2021

COPD

View full text Add to dashboard Cite

Autophagy plays essential roles in the development of COPD. We aim to identify and validate the potential autophagy-related genes of COPD through bioinformatics analysis and experiment validation. Methods: The mRNA expression profile dataset GSE38974 was obtained from GEO database. The potential differentially expressed autophagy-related genes of COPD were screened by R software. Then, protein-protein interactions (PPI), correlation analysis, gene-ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were applied for the differentially expressed autophagy-related genes. Finally, RNA expression of top five differentially expressed autophagy-related genes was validated in blood samples from COPD patients and healthy controls by qRT-PCR. Results: A total of 40 differentially expressed autophagy-related genes (14 up-regulated genes and 26 down-regulated genes) were identified between 23 COPD patients and 9 healthy controls. The PPI results demonstrated that these autophagy-related genes interacted with each other. The GO and KEGG enrichment analysis of differentially expressed autophagy-related genes indicated several enriched terms related to autophagy and mitophagy. The results of qRT-PCR showed that the expression levels of HIF1A, CDKN1A, BAG3, ERBB2 and ATG16L1 in COPD patients and healthy controls were consistent with the bioinformatics analysis results from mRNA microarray. Conclusion: We identified 40 potential autophagy-related genes of COPD through bioinformatics analysis. HIF1A, CDKN1A, BAG3, ERBB2 and ATG16L1 may affect the development of COPD by regulating autophagy. These results may expand our understanding of COPD and might be useful in the treatment of COPD.

show abstract

“…RANTES/CCL5 is also associated with airway inflammation and airway hyperresponsiveness, as we and others previously reported, 19,20 which is also supported by the present results. Interestingly, a high level of VEGF-A, which is correlated with decreased pulmonary function, 21 was also significantly more common in overweight patients with asthma, supporting the lower FVC and FEV1, compared to non-overweight asthma patients. There are two limitations in this study.…”

Section: Discussionmentioning

confidence: 72%

<p>Biomarkers for Overweight in Adult-Onset Asthma</p>

Tashiro

Takahashi

Sadamatsu

et al. 2020

JAA

View full text Add to dashboard Cite

Overweight and obesity are associated with one of the severe phenotypes of asthma, with an increased rate of exacerbations, low level of lung function, and reduced response to corticosteroid therapy. The present study focused on identifying useful biomarkers of severity in overweight patients with adult-onset asthma using real-world data. Patients and Methods: A total of 56 patients with adult-onset asthma who visited Saga University Hospital between 2018 and 2019 were retrospectively reviewed. Overweight was defined as a body mass index (BMI) greater than 25 kg/m 2. Blood eosinophils, cytokines, and chemokines were compared between non-overweight asthma and overweight asthma patients. Results: Overweight asthma patients had a higher annual exacerbation rate, lower pulmonary function even when treated frequently with high-dose inhaled corticosteroids, and a significantly lower percentage of eosinophils and lower eosinophil count compared to nonoverweight asthma patients (p<0.01, p=0.03). Moreover, the percentage of eosinophils was significantly negatively correlated with BMI (ρ=−0.38, p<0.01) (Figure 1). On serum cytokine and chemokine analyses, the overweight asthma group included significantly more patients with a lower level of tissue growth factor α (TGF-α) (1.1 pg/mL) and higher levels of hsIL-6 (2.5 pg/mL), RANTES/CCL5 (298.5 pg/mL), and vascular endothelial growth factor A (VEGF-A) (63.7 pg/mL), than the non-overweight asthma group (p=0.02, p<0.01, p=0.02, p=0.01, respectively). Conclusion: The present study showed that overweight patients with adult-onset asthma were characterized by a higher rate of annual exacerbations and worse lung function despite treatment with high-dose inhaled corticosteroids and lower blood eosinophil counts than nonoverweight patients with asthma. On blood cytokine and chemokine analyses, a low level of TGF-α and high levels of hsIL-6, RANTES/CCL5, and VEGF-A might be biomarkers reflecting the pathophysiology in overweight patients with asthma.

show abstract

<p>Serum IL-8 and VEGFA are Two Promising Diagnostic Biomarkers of Asthma-COPD Overlap Syndrome</p>

Cited by 24 publications

References 27 publications

Update on Asthma–COPD Overlap (ACO): A Narrative Review

Update on Asthma–COPD Overlap (ACO): A Narrative Review

Identification and Validation of Autophagy-Related Genes in Chronic Obstructive Pulmonary Disease

<p>Biomarkers for Overweight in Adult-Onset Asthma</p>

Contact Info

Product

Resources

About